That could represent further problems for Eyetech (nasdaq: EYET - news - people ), which, along with Pfizer (nyse: PFE - news - people ), already sells a treatment called Macugen for the disease--age-related macular degeneration (AMD).
FORBES: More Eye-Opening Data From Genentech